stock downgrade
Evercore, Barclays Downgrade Agilent Shares
The investment banks said they made the changes in response to lower demand for instruments in biopharma industries and lower economic activity in China.
BTIG Downgrades Oncocyte to Neutral Following News of CEO Departure
In an announcement late Wednesday, the company said Ronnie Andrews had stepped down, marking the firm's third major executive to depart in recent months.
Canaccord Downgrades T2 Biosystems to Hold
The investment bank cited a soft Q3 outlook, slower-than-expected pipeline progress, and capital and liquidity concerns raised in the company's preliminary quarterly results.
Evercore ISI Downgrades PerkinElmer Shares to In Line
The bank previously had an Outperform Rating on PerkinElmer, and it also lowered its price target for the firm's stock to $150 per share from $175 per share.
William Blair Downgrades Lucira Health to Market Perform
As a result of the downgrade, the bank also significantly reduced revenue and volume estimates for 2021 and 2022.